{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:24:33Z","timestamp":1740140673168,"version":"3.37.3"},"reference-count":9,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T00:00:00Z","timestamp":1627603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Ruxolitinib, a selective inhibitor of Janus kinases 1 and 2, is increasingly being used in allogeneic hematopoietic cell transplantation (HCT) recipients following its approval by the U.S. Food and Drug Administration for the treatment of steroid-refractory acute graft-versus-host disease. Although there is extensive experience using ruxolitinib for patients with myeloproliferative neoplasms, the biologic effects and clinical implications of its dosing, tapering, and discontinuation for allogeneic HCT recipients are incompletely characterized. We describe three allogeneic HCT recipients who developed acute hypoxemic respiratory failure within 3 months of ruxolitinib discontinuation. Radiographic findings included marked bilateral ground-glass opacities. Systemic corticosteroids and reinitiation of ruxolitinib resulted in rapid clinical improvement in all three patients. All three patients achieved a significant clinical response, with decrease in oxygen requirement and improvement in radiographic changes. Given the increasing use of ruxolitinib in allogeneic HCT recipients, there is significant impetus to characterize the biologic and clinical effects resulting from discontinuation of ruxolitinib, to better tailor treatment plans and prevent potential adverse effects.<\/jats:p>","DOI":"10.1002\/onco.13903","type":"journal-article","created":{"date-parts":[[2021,7,17]],"date-time":"2021-07-17T09:00:29Z","timestamp":1626512429000},"page":"e2082-e2085","source":"Crossref","is-referenced-by-count":2,"title":["Hypoxemic Respiratory Failure Following Ruxolitinib Discontinuation in Allogeneic Hematopoietic Cell Transplantation Recipients"],"prefix":"10.1093","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4861-3159","authenticated-orcid":false,"given":"Annabelle J.","family":"Anandappa","sequence":"first","affiliation":[{"name":"Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela S.","family":"Hobbs","sequence":"additional","affiliation":[{"name":"Center for Leukemia, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bimalangshu R.","family":"Dey","sequence":"additional","affiliation":[{"name":"Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3556-1495","authenticated-orcid":false,"given":"Areej","family":"El-Jawahri","sequence":"additional","affiliation":[{"name":"Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6774-5694","authenticated-orcid":false,"given":"Matthew J.","family":"Frigault","sequence":"additional","affiliation":[{"name":"Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven L.","family":"McAfee","sequence":"additional","affiliation":[{"name":"Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul V.","family":"O'Donnell","sequence":"additional","affiliation":[{"name":"Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas R.","family":"Spitzer","sequence":"additional","affiliation":[{"name":"Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9554-1058","authenticated-orcid":false,"given":"Yi-Bin","family":"Chen","sequence":"additional","affiliation":[{"name":"Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7994-8974","authenticated-orcid":false,"given":"Zachariah","family":"DeFilipp","sequence":"additional","affiliation":[{"name":"Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,7,30]]},"reference":[{"key":"2022011714504246200_onco13903-bib-0001","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/blood.2020004823","article-title":"Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): A multicenter, open-label phase 2 trial","volume":"135","author":"Jagasia","year":"2020","journal-title":"Blood"},{"key":"2022011714504246200_onco13903-bib-0002","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N Engl J Med"},{"key":"2022011714504246200_onco13903-bib-0003","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1634\/theoncologist.2019-0627","article-title":"FDA approval summary: Ruxolitinib for treatment of steroid-refractory acute graft-versus-host disease","volume":"25","author":"Przepiorka","year":"2020","journal-title":"Oncologist"},{"key":"2022011714504246200_onco13903-bib-0004","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.4065\/mcp.2011.0518","article-title":"Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis","volume":"86","author":"Tefferi","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"2022011714504246200_onco13903-bib-0005","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s12185-014-1628-5","article-title":"Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation","volume":"100","author":"Beauverd","year":"2014","journal-title":"Int J Hematol"},{"key":"2022011714504246200_onco13903-bib-0006","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/ajh.24775","article-title":"A life-threatening ruxolitinib discontinuation syndrome","volume":"92","author":"Coltro","year":"2017","journal-title":"Am J Hematol"},{"key":"2022011714504246200_onco13903-bib-0007","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1182\/bloodadvances.2020002097","article-title":"The development of ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease","volume":"4","author":"Zeiser","year":"2020","journal-title":"Blood Adv"},{"key":"2022011714504246200_onco13903-bib-0008","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41408-020-00392-1","article-title":"Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis","volume":"11","author":"Palandri","year":"2021","journal-title":"Blood Cancer J"},{"key":"2022011714504246200_onco13903-bib-0009","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41375-020-01107-y","article-title":"High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib","volume":"35","author":"Barbui","year":"2021","journal-title":"Leukemia"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/onco.13903","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/onco.13903","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/11\/e2082\/42204113\/oncolo_26_11_e2082.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/11\/e2082\/42204113\/oncolo_26_11_e2082.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T14:53:22Z","timestamp":1642431202000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/26\/11\/e2082\/6508808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,30]]},"references-count":9,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,7,30]]},"published-print":{"date-parts":[[2021,11,1]]}},"URL":"https:\/\/doi.org\/10.1002\/onco.13903","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"type":"print","value":"1083-7159"},{"type":"electronic","value":"1549-490X"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2021,7,30]]}}}